Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

  1. Gianni, L.
  2. Mansutti, M.
  3. Anton, A.
  4. Calvo, L.
  5. Bisagni, G.
  6. Bermejo, B.
  7. Semiglazov, V.
  8. Thill, M.
  9. Chacon, J.I.
  10. Chan, A.
  11. Morales, S.
  12. Alvarez, I.
  13. Plazaola, A.
  14. Zambetti, M.
  15. Redfern, A.D.
  16. Dittrich, C.
  17. Dent, R.A.
  18. Magazzu, D.
  19. De Fato, R.
  20. Valagussa, P.
  21. Tusquets, I.
Revue:
JAMA Oncology

ISSN: 2374-2445,  2374-2437

Année de publication: 2018

Volumen: 4

Número: 3

Pages: 302-308

Type: Article

DOI: 10.1001/JAMAONCOL.2017.4612 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus